Biogen's $3 billion alliance with Sage Therapeutics has suffered another setback after their drug for essential tremor failed to move the needle in a phase 2 study. Topline results from the ...

Sage Therapeutics has said it will stop the development of dalzanemdor in Alzheimer's disease, a few months after pulling the plug on the drug in Parkinson's disease. The decision, prompted by a ...

Sage Therapeutics, Inc. (SAGE ... announced a strategic reorganization wherein it decided to focus on the commercialization of its depression drug Zurzuvae (zuranolone), which is marketed in ...

SAGE-689 is under clinical development by Sage Therapeutics and currently in Phase I for Unspecified Central Nervous System Disorders.

Drug manufacturers Sage Therapeutics and Biogen said the pill is expected to be available later this year. No price has yet been announced. Similar to other forms of depression, symptoms of ...